.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
McKesson
Merck
Novartis
Express Scripts
McKinsey
Daiichi Sankyo
US Army
Deloitte
AstraZeneca

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204095

« Back to Dashboard
NDA 204095 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Alembic Pharms Ltd, Sandoz Inc, Actavis Labs Fl, Lupin Ltd, West-ward Pharms Int, and Mylan Pharms Inc, and is included in seven NDAs. It is available from six suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for NDA: 204095

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 204095

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL 204095 ANDA Mylan Pharmaceuticals Inc. 0378-4230 0378-4230-77 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-4230-77)
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL 204095 ANDA Mylan Pharmaceuticals Inc. 0378-4230 0378-4230-93 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-4230-93)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG BASE
Approval Date:Jun 29, 2015TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Jun 29, 2015TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
AstraZeneca
Baxter
Dow
Citi
Accenture
Deloitte
McKinsey
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot